A very recent review suggested that chondrosarcoma patients might benefit from antiangiogenic therapy and that tumors harboring isocitrate dehydrogenase 1 (IDH1)-mutations might benefit from treatment with IDH1-inhibitors. This evidence concerns the gene IDH1 and chondrosarcoma.